Introduction: Uterine fibroids are benign growths localized in the uterus that occur in women of child-bearing age and are treated with UAE, MRI FUS and medical interventions. These modalities are also known to differ in terms of their effectiveness, risk factor as well as patient satisfaction. Aim: The objective of this research is to compare UAE, MRgFUS, and pharmacological treatment and determine their efficacy, side effects and patients’ satisfaction. Methodology: The paper adopts the systematic review method involving articles in the period of 2010 to 2023. Studies were evaluated using results like the size of the fibroids at baseline and follow up, changes in symptoms, complication rates and recurrences. Results: The results revealed that the UAE has the ability to achieve the highest fibroid size reduction; (75%) and symptom improvement; (85%) as well as a 90% satisfaction rate in the UAE. In the current study, MRgFUS ranked middle (55% tumor size decrease, 70% onset discomfort abatement) and the fastest recuperation period (3 days). Pharmacological interventions had less success in the size (40% reduction) and symptom (60% reduction) therefore having the highest recurrence level (30%). Conclusion: Among those, UAE provides the most long-term relief, whereas MRgFUS is proved to be safe and allows recovery quickly. Pharmacological management is specifically beneficial in managing symptoms usually for a short time. However, it is still important to remember that a client centered approach should still be used in order to provide the best results.